Signal Transduction
Stem Cells
Signaling Pathways
Product Type
All Products
New Products
Small Molecules
Peptides
Controlled Substances
Toxins
Caged Compounds
Fluorescent Probes
Screening Libraries
Ligand Sets
Other Product Types
Research Area
Cancer
Cardiovascular System
Endocrinology
Immunology
Neuroscience
Pain & Inflammation
Respiratory System
FPL 64176Cat. No. 1403 |
Price and AvailabilityBy clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy. |
|
Chemical Name: 2,5-Dimethyl-4-[2-(phenylmethyl)benzoyl]-1H-pyrrole-3-carboxylic acid methyl ester |
Biological Activity
Potent activator of L-type Ca2+ channels (EC50 = 16 nM). 40-fold more potent than Bay K 8644 (Cat. No. 1544) as a positive inotrope in guinea pig atria.Certificate of Analysis / Safety Data Sheet
References
Zheng et al (1991) Pharmacological, radioligand binding, and electrophysiological characteristics of FPL 64176, a novel nondihydropyridine Ca2+ channel activator, in cardiac and vascular preparations. Mol.Pharmacol. 40 734. PMID: 1719369.
Baxter et al (1993) Discovery and synthesis of methyl 2,5-dimethyl-4-[2-(phenylmethyl)benzoyl]-1H-pyrrole-3-carboxylate (FPL 64176) and analogues: the first examples of a new class of calcium channel activator. J.Med.Chem. 36 2739. PMID: 7692047.
Rampe et al (1993) Comparison of the in vitro and in vivo cardiovascular effects of two structurally distinct Ca++ channel activators, BAY K 8644 and FPL 64176. J.Pharmacol.Exp.Ther. 265 1125. PMID: 7685384.
If you know of a relevant citation for this product please let us know.
View Related Products by Target
Keywords: FPL 64176, supplier, Potent, activator, Ca2+, channels, L-type, Calcium, CaV, Channels, voltage-gated, voltage-dependent, FPL64176
Quick Order
Find multiple products by catalog number
Pain Research Guide
Reserve your free copy
Highlights over 280 products for Pain research. Reserve copy
Calcium Imbalance and Neuroprotective Targets
Written by E. Besancon et al
'Calcium Imbalance and Neuro-protective Targets in Cerebral Ischemia & Brain Injury' highlights the key targets involved in stroke, trauma and neurodegeneration.
Antidepressants - Current and Future Targets
Written by P. Skolnich et al
'Antidepressants - Current and Future Targets' provides an overview of the current and future targets for the treatment of major depressive disorder.
New Products in this Area
Stretch-activated calcium channel blocker; calcium-sensing receptor agonist
ProTx ICaV3.1 channel blocker; also inhibits NaV1.8 and KV2.1
20% Discount*
Potent, selective LRRK2 inhibitor
Tocris is the first to launch GSK2578215A, licensed from GlaxoSmithKline, for the study of Parkinson's Disease.